Skip to main content

Table 2 Genotyping results from isolates in the in vivo therapeutic efficacy study and in vitro drug assay

From: Chloroquine efficacy studies confirm drug susceptibility of Plasmodium vivax in Chennai, India

Study   Subjects enrolled (N) Pvmdr1 haplotypesa Microsatellite genotyping
Isolates successfully genotyped (n) 958M/Y976/1076L (n (%)) 958M/Y976/F1076 (n (%)) Isolates successfully genotyped (n) Multiclonal infections (n (%)) Clones (n) Multiplicity of infectionc
in vivo therapeutic efficacy:        
  Day 0 125 33 33 (100) 0 (0.0) 33 5 (15.2) 38 1.15
  Day 3 19 0 - - 0 - - -
  Day Other 17 15 14 (93.3) 1 (6.7) 17 3b (17.6) 21 1.24
  Total 125 48 47 (97.9) 1 (2.1) 50 8 (16.0) 59 1.18
in vitro drug assay:        
  Group 1 51 9 8 (88.9) 1 (11.1) 10 4 (40.0) 14 1.40
  Group 2 17 9 9 (100) 0 (0.0) 10 2 (20.0) 12 1.20
  Total 68 18 17 (94.4) 1 (5.6) 20 6 (30.0) 26 1.30
  1. aGenBank accession nos: KC818349-KC818412; Pvmdr1 haplotype of the CQ sensitive Salvador I reference strain is T958/Y976/F1076.
  2. bOf the three multiclonal infections, two had two alleles at more than one locus (double infection) and one had three alleles at more than one locus (triple infection).
  3. cMultiplicity of infection is the total number of clones detected divided by the total number of infections.